Clinical trials: Atopic Dermatitis
Atopic Dermatitis
Tolerance and Efficacy of Formulation 609580 20 Versus Formulation 609209 in Children With Atopic Dermatitis
Atopic dermatitis is one of the most frequent skin diseases. The disease is often worst during winter months when the skin is drier. Mild to moderate cases of atopic dermatitis are often controlled by a moisturizer alone.
- Trial name
- NCT00931411
- Testing
- Formulation 609580 20, Formulation 609209 (Lipikar Baume)
- Where
- 5 sites in Canada
- Volunteers
- 73 people
- Sponsor
- Cosmetique Active International
Dermatitis, Atopic
Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)
This study is a 2-part (parts A and B) phase 2/3 study to evaluate the safety, pharmacokinetics (PK) and efficacy of dupilumab in participants 6 months to less than 6 years of age with moderate-to-severe atopic dermatitis (AD).
- Trial name
- Liberty AD (NCT03346434)
- Testing
- Dupilumab
- Where
- 48 sites in United States, Germany and 2 more
- Volunteers
- 202 people
- Sponsor
- Regeneron Pharmaceuticals
Atopic Dermatitis, Eczema
A Trial of a Botanical Drug Containing East Indian Sandalwood Oil (EISO) For Treatment of Atopic Dermatitis
This trial will be a double-blind, randomized, placebo-controlled, safety, tolerability and efficacy trial of SAN007 (5% East Indian sandalwood oil in a cream formulation) treatment regimen when administered daily for up to 28…
- Trial name
- NCT02871479
- Testing
- SAN007 5% cream, SAN007 10% cream
- Where
- 5 sites in United States
- Volunteers
- 71 people
- Sponsor
- Santalis Pharmaceuticals, Inc.
Moderate-to-Severe Atopic Dermatitis, Atopic Eczema
Dupilumab in Adolescent and Adult Skin of Color Participants: Open-label Moderate-to-severe Eczema Trial
The study is focused on skin of color participants who have moderate-to-severe atopic dermatitis. Atopic dermatitis, also referred to as eczema, is a condition that causes the skin to become itchy, dry, and cracked.
- Trial name
- DISCOVER (NCT05590585)
- Testing
- dupilumab, Topical emollient (moisturizer)
- Where
- 30 sites in United States
- Volunteers
- 124 people
- Sponsor
- Regeneron Pharmaceuticals
Chronic Hand Eczema
Phase 2b Dose-ranging Trial to Evaluate Delgocitinib Cream 1, 3, 8, and 20 mg/g Compared to Delgocitinib Cream Vehicle Over a 16-week Treatment Period in Adult Subjects With Chronic Hand Eczema
The purpose of this research trial was to test different strengths of a new trial medication, delgocitinib cream 1, 3, 8, and 20 mg/g, and to investigate how treatment with delgocitinib cream affects chronic hand eczema.
- Trial name
- NCT03683719
- Testing
- Delgocitinib cream, Delgocitinib cream vehicle
- Where
- 28 sites in United States, Denmark and 1 more
- Volunteers
- 258 people
- Sponsor
- LEO Pharma
Atopic Dermatitis
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy and combination therapy treatment in adolescent participants.
- Trial name
- ROCKET-ASTRO (NCT05704738)
- Testing
- Rocatinlimab
- Where
- 246 sites in United States, Belgium and 20 more
- Volunteers
- 532 people
- Sponsor
- Amgen
Atopic Dermatitis
Adherence to Topical Hydrocortisone 17-butyrate 0.1% (Locoid®) Using Different Vehicles in Adults With Atopic Dermatitis
The purpose of this research study is to better understand adherence to Locoid when people use it to treat atopic dermatitis.
- Trial name
- NCT00693693
- Testing
- hydrocortisone 17-butyrate 0.1% Cream preparation, hydrocortisone 17-butyrate 0.1% Ointment preparation, hydrocortisone 17-butyrate 0.1% Lipocream preparation
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- Wake Forest University
Atopic Dermatitis
A Study Evaluating Rocatinlimab in Moderate-to-severe Atopic Dermatitis (ROCKET-IGNITE)
The purpose of this study is to evaluate the efficacy and safety of rocatinlimab in monotherapy treatment.
- Trial name
- ROCKET-Ignite (NCT05398445)
- Testing
- Rocatinlimab
- Where
- 202 sites in United States, Argentina and 19 more
- Volunteers
- 769 people
- Sponsor
- Amgen
Dermatitis, Atopic, Eczema, Atopic
Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)
This is a parallel-group, randomized, active-controlled, double-blind, Phase 4 trial comparing three creams in the treatment of impetiginous eczema: Arm A: QUADRIDERME® cream (betamethasone diproprionate, clotrimazole, and…
- Conditions
- Dermatitis, Atopic, Eczema, Atopic, Skin Diseases, Eczematous
- Trial name
- NCT00671528
- Testing
- Cream (betamethasone diproprionate, clotrimazole, and gentamicin sulfate), Cream (betamethasone diproprionate and gentamicin), Cream (betamethasone diproprionate)
- Volunteers
- 3 people
- Sponsor
- Organon and Co
Psoriasis, Atopic Dermatitis
Study to Evaluate Effect of Pandel Cream 0.1% on HPA Axis in Pediatric and Adult Population
The purpose of this study is to determine the effect of Pandel® (hydrocortisone probutate cream) Cream 0.1% on the Hypothalamic Pituitary Adrenal (HPA) axis in pediatric and adult subjects with either psoriasis or atopic…
- Trial name
- NCT01137032
- Testing
- Pandel Cream 0.1%
- Where
- 3 sites in United States
- Volunteers
- 19 people
- Sponsor
- Fougera Pharmaceuticals Inc.
Atopic Dermatitis
To Evaluate the Safety and Efficacy of a New Device in the Management of Mild to Moderate Atopic Dermatitis in Children
The purpose of this study was to evaluate the safety of the investigational study product and see how well it works to relieve signs and symptoms of children with mild to moderate Atopic Dermatitis (AD), also known as eczema, in…
- Trial name
- NCT00886587
- Testing
- F# 11054-010, F# 10495-053
- Where
- 2 sites in United States
- Volunteers
- 82 people
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Atopic Dermatitis, Skin Diseases
Study to Assess the Efficacy and Safety of Orismilast in Atopic Dermatitis (ADESOS)
This study investigates 3 different doses of orismilast modified release compared to placebo in adult patients with moderate-to-severe atopic dermatitis.
- Trial name
- NCT05469464
- Testing
- Orismilast modified release tablets
- Where
- 48 sites in United States, Germany and 2 more
- Volunteers
- 235 people
- Sponsor
- UNION therapeutics
Atopic Dermatitis
The Effectiveness of Montelukast on Atopic Dermatitis in Koreans
The purpose of this study is to assess the clinical effectiveness of Montelukast in children (2~6 years old) with atopic dermatitis and identify the pathophysiologic background of Montelukast on the role of modulating the atopic…
- Trial name
- NCT00903357
- Where
- South Korea
- Volunteers
- 54 people
- Sponsor
- Pyun BokYang
Dermatitis, Atopic
Efficacy and Safety of AN2728 Topical Ointment to Treat Adolescents With Atopic Dermatitis
The purpose of this study is to determine the safety and efficacy of AN2728 Topical Ointment, 2% and 0.5%, administered once a day (QD) or twice a day (BID), in the treatment of adolescents with atopic dermatitis (AD)
- Trial name
- NCT01602341
- Testing
- AN2728 Topical Ointment, 2% QD, AN2728 Topical Ointment, 0.5% QD, AN2728 Topical Ointment, 2% BID
- Where
- 17 sites in United States, Australia
- Volunteers
- 86 people
- Sponsor
- Pfizer
Dermatitis
Clinical Investigation on the Efficacy and Safety of Relizema Ecofoam
The scope of this open label clinical trial is to evaluate and confirm the performance of Relizema ecofoam in the improvement of the dermatitis severity.
- Trial name
- NCT05001139
- Testing
- Relizema ecofoam
- Where
- Italy
- Volunteers
- 13 people
- Sponsor
- Relife S.r.l.
Atopic Dermatitis
A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)
The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.
- Trial name
- NCT03921411
- Testing
- Nemolizumab
- Where
- 10 sites in United States
- Volunteers
- 20 people
- Sponsor
- Galderma R&D
Atopic Dermatitis
Study of TER-101 Topical Ointment in Subjects With Atopic Dermatitis
This Phase 2 study will assess efficacy, safety, and tolerability of TER-101 ointment and vehicle twice daily for 28 days in adult and adolescent subjects with mild to moderate atopic dermatitis.
- Trial name
- NCT04753034
- Testing
- TER-101, Vehicle
- Where
- 12 sites in United States
- Volunteers
- 63 people
- Sponsor
- Teres Bio, Inc.
Eczema
Blue Light for Treating Eczema
Monocenter, randomized, intraindividual, open label, exploratory study comparing 4 weeks of treatment with 453nm blue light with no treatment in patients with Eczema.
- Trial name
- NCT02002871
- Testing
- PSO-CT02 device
- Where
- Germany
- Volunteers
- 21 people
- Sponsor
- Philips Electronics Nederland BV
Eczema
Efficacy and Safety of a Retinoid in the Treatment of Severe Chronic Hand Eczema
The purpose of this study is to investigate the safety and efficacy of alitretinoin in the treatment of severe chronic hand eczema that does not respond to treatment with potent topical steroids.
- Trial name
- HANDEL (NCT00817063)
- Testing
- alitretinoin
- Where
- 70 sites in United States
- Volunteers
- 599 people
- Sponsor
- Stiefel, a GSK Company
Atopic Dermatitis (AD)
Tolerance Evaluation of a Nighttime Moisturizing Balm on Babies and Adults With Eczema
The purpose of this 14-day, two phase clinical study is to test the tolerance of a new over-the-counter moisturizing balm on subjects with eczema.
- Trial name
- NCT02357940
- Testing
- Experimental Product
- Where
- 2 sites in United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer Inc. (J&JCI)